1. 9. 2014

“Making choices, creating changes” – Krka’s symposium in Barcelona

3 min. read

We make choices every day and while some may seem insignificant, others can create a change in peoples’ lives. To discuss how to make medical choices in every day clinical practice and choose an optimal treatment path for patients with hyperlipidemia, Krka organized an international symposium Making choices, creating changes.

Audience during a lively discussion

It was held on 30 August in Barcelona during the Congress of the European Society of Cardiology. Krka’s Medical Director Breda Barbič Žagar welcomed around 230 guests from 17 countries and presented our company and devotion to provide high-quality medicines with proven efficacy and safety in our own clinical studies.

In the scientific part of the symposium chaired by the eminent expert in the field of cardiovascular prevention Prof. Željko Reiner, participants listened to the interesting lectures. Prof. Gheorghe-Andrei Dan from Romania gave the opening lecture Choosing the right medicine, in which he presented the advantages of atorvastatin and rosuvastatin in the treatment of hyperlipidemia. The symposium continued with the lecture Choosing the right dose by Prof. Krzysztof J. Filipiak from Poland, who pointed out that a good part of patients still do not achieve target lipid levels and that higher doses of statins are needed to achieve the maximum potential of statin treatment. The following topic Choosing the right words was discussed by Assist. Borut Jug from Slovenia, who presented key approaches on how to explain the importance of statin treatment to patients and in this way increase treatment compliance.

In the closing lecture Choosing the right path, Krka’s Product Manager Sanja Brus presented the position of Krka’s statins in international clinical practice. As the first producer, Krka offers statins in two additional doses, atorvastatin 30 and 60 mg and rosuvastatin 15 and 30 mg. In particular, she highlighted the results from the most recent clinical study ROSU-PATH, which confirm the advantages of using additional doses in clinical practice.

The symposium was concluded by a discussion based on questions from the audience, expressing great interest in the topics discussed at the event.